Evidence map›Paper›PMID 27900576›Full record

ArticleNeurochemical research2017

Time Course, Behavioral Safety, and Protective Efficacy of Centrally Active Reversible Acetylcholinesterase Inhibitors in Cynomolgus Macaques.

Lindsey R Hamilton, Steven C Schachter, Todd M Myers

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Percentile schedules to shape touchscreen response locations in cynomolgus macaques.Journal of the experimental analysis of behavior · 2026
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Lindsey R HamiltonDepartment of Psychology, University of Colorado Denver, Denver, CO, 80217, USA.
Steven C SchachterDepartments of Neurology Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Harvard Medical School, Consortia for Improving Medicine with Innovation and Technology, 125 Nashua Street, 3rd Floor, Boston, MA, 02114, USA. sschacht@bidmc.harvard.edu.
Todd M MyersNeurobehavioral Toxicology Branch, Analytical Toxicology Division, United States Army Medical Research Institute of Chemical Defense (USAMRICD), 2900 Ricketts Point Rd, Aberdeen Proving Ground, Aberdeen, MD, 21010, USA.
Harvard University · USUnited States Army · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galantamine hydrobromide and (-)huperzine A, centrally active reversible acetylcholinesterase inhibitors, are potentially superior to the current standard, pyridostigmine bromide, as a pretreatment for organophosphorus chemical warfare nerve agent intoxication. Galantamine, huperzine, and pyridostigmine were compared for time course of acetylcholinesterase inhibition in 12 cynomolgus macaques. Although both galantamine and huperzine shared a similar time course profile for acetylcholinesterase inhibition, huperzine was 88 times more potent than galantamine. The dose for 50% acetylcholinesterase inhibition (ID

Indexed as

AlkaloidsAnimalsChemical Warfare AgentsCholinesterase InhibitorsConvulsantsMacaca fascicularisMalePyridostigmine BromideReaction TimeSeizuresSesquiterpenesSomanTime FactorsTreatment OutcomeAlkaloidsChemical Warfare AgentsCholinesterase InhibitorsConvulsantshuperzine APyridostigmine BromideSesquiterpenesSomanAcetylcholinesteraseBehavioral toxicityGalantamineHuperzineNerve agentPyridostigmine bromide

Identifiers

PMID27900576
OpenAlexW2558090332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.